MISOPROSTOL (MISOPROSTOLUM)

Draft proposal for *The International Pharmacopoeia*

(November 2015)

**REVISED DRAFT FOR COMMENT**

Should you have any comments on this draft please send these to Dr Herbert Schmidt, Medicines Quality Assurance, Technologies, Standards and Norms, Department of Essential Medicines and Health Products, World Health Organization, 1211 Geneva 27, Switzerland; fax: (+41 22) 791 4730 or e-mail: schmidt@who.int by 15 February 2016.

In order to speed up the process for receiving draft monographs and for sending comments, please let us have your e-mail address (to bonnyw@who.int) and we will add it to our electronic mailing list. Please specify if you wish to receive monographs.

© World Health Organization 2015

All rights reserved.

This draft is intended for a restricted audience only, i.e. the individuals and organizations having received this draft. The draft may not be reviewed, abstracted, reproduced, transmitted, distributed, translated or adapted, in part or in whole, in any form or by any means outside these individuals and organizations (including the organizations’ concerned staff and member organizations) without the permission of the World Health Organization. The draft should not be displayed on any website.

Please send any request for permission to:

Dr Sabine Kopp, Group Lead, Medicines Quality Assurance, Technologies, Standards and Norms, Department of Essential Medicines and Health Products, World Health Organization, CH-1211 Geneva 27, Switzerland. Fax: (41-22) 791 4730; email: koppins@who.int.

The designations employed and the presentation of the material in this draft do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by the World Health Organization to verify the information contained in this draft. However, the printed material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall the World Health Organization be liable for damages.

This draft does not necessarily represent the decisions or the stated policy of the World Health Organization.
### SCHEDULE FOR THE ADOPTION PROCESS OF DOCUMENT QAS/15.602/Rev.1

*Draft proposal for The International Pharmacopoeia: Misoprostol (Misoprostolum)*

<table>
<thead>
<tr>
<th>Event</th>
<th>Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>First draft received from collaborating laboratory</td>
<td>2014</td>
</tr>
<tr>
<td>Preliminary version presented to WHO Expert Committee on Specifications for Pharmaceutical Preparations (ECSPP)</td>
<td>October 2014</td>
</tr>
<tr>
<td>First draft sent out for public consultation</td>
<td>January–March 2015</td>
</tr>
<tr>
<td>Discussion at informal consultation on screening, sampling and specifications of new medicines and preparation of second draft (Revision 1)</td>
<td>13–15 April 2015</td>
</tr>
<tr>
<td>Presentation to WHO ECSPP for discussion</td>
<td>October 2015</td>
</tr>
<tr>
<td>Revision 1 sent out for public consultation</td>
<td>November 2015 – February 2016</td>
</tr>
<tr>
<td>Review of the comments received by a subgroup of experts</td>
<td>February 2016</td>
</tr>
<tr>
<td>Further follow-up action as required and as recommended by the members of the ECSPP meeting</td>
<td></td>
</tr>
</tbody>
</table>
Draft proposal for The International Pharmacopoeia

MISOPROSTOL
(MISOPROSTOLUM)

[Note from the Secretariat. The following monograph is proposed for inclusion in The International Pharmacopoeia.]

Molecular formula. $C_{22}H_{38}O_5$

Relative molecular mass. 382.5

Graphic formula

Chemical name.
Mixture of methyl $rac$-$7$-{$(1R,2R,3R)-3$-hydroxy-$2$-{$(1E,4R)$-4$-hydroxy$-4$-methyloct$-1$-en-$1$-yl}$-5$-oxocyclopentyl}$heptanoate and methyl $rac$-$7$-{$(1R,2R,3R)-3$-hydroxy-$2$-{$(1E,4S)$-4$-hydroxy$-4$-methyloct$-1$-en-$1$-yl}$-5$-oxocyclopentyl}$heptanoate; CAS Reg. No. 59122-46-2.

Description. Clear, colourless or yellowish, oily liquid.

Solubility. Practically insoluble in water R, soluble in dehydrated ethanol R, sparingly soluble in acetonitrile R.

Category. Prostaglandin (PGE$_1$) analogue.

Storage. Misoprostol neat oil should be kept in a tightly sealed container and stored at a temperature between -25 and -10 °C.

Additional information. Misoprostol is hygroscopic. It is gradually degraded at room temperature, the degradation being faster at higher temperatures.
Requirements

Definition. Misoprostol contains not less than 96.5% and not more than 102.0% of C$_{22}$H$_{38}$O$_5$ with reference to the anhydrous substance.

Identity tests

Either test A or tests B and C may be applied.

A. Carry out the examination as described under 1.7 Spectrophotometry in the infrared region. The infrared absorption spectrum is concordant with the spectrum obtained from misoprostol RS or with the reference spectrum of misoprostol.

B. Carry out the test as described under 1.14.1 Thin-layer chromatography using silica gel R3 as the coating substance and a mixture of 8 volumes of toluene R, 2 volumes of ethyl acetate R, 1 volume of dehydrated ethanol R and 0.1 volume of glacial acetic acid R as the mobile phase, prepared immediately before use. Apply separately to the plate 100 µL of each of the following two solutions in dehydrated ethanol R. For solution (1) use 0.1 mg of the test substance per mL. For solution (2) use 0.1 mg of misoprostol RS per mL. After removing the plate from the chromatographic chamber allow it to dry in air, expose it to the vapour of iodine R and examine the chromatogram in daylight.

The principal spot obtained with solution (1) corresponds in position, appearance and intensity to that obtained with solution (2).

C. Carry out the test as described under 1.14.4 High-performance liquid chromatography using the conditions given under “Assay”. The retention time of the principal peak in the chromatogram obtained from solution (1) corresponds to the retention time of the peak due to misoprostol in the chromatogram obtained from solution (2).
**Water.** Determine as described under 2.8 *Determination of water by the Karl Fischer method*, method A, using 1.0 mL of a 10 mg per mL solution of the test substance in dehydrated methanol R; the water content is not more than 10 mg/g.

**Related substances**

Prepare fresh solutions and perform the tests without delay.

Carry out the test as described under 1.14.4 *High performance liquid chromatography* using a stainless steel column (15 cm × 4.6 mm) packed with octadecylsilyl silica gel (5 μm).¹

Use the following conditions for gradient elution:

<table>
<thead>
<tr>
<th>Time (min)</th>
<th>Mobile phase A (%) v/v</th>
<th>Mobile phase B (%) v/v</th>
<th>Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td>0–5</td>
<td>100</td>
<td>0</td>
<td>isocratic</td>
</tr>
<tr>
<td>5–15</td>
<td>100 to 65</td>
<td>0 to 35</td>
<td>linear gradient</td>
</tr>
<tr>
<td>15–22</td>
<td>65</td>
<td>35</td>
<td>isocratic</td>
</tr>
<tr>
<td>22–25</td>
<td>65 to 0</td>
<td>35 to 100</td>
<td>linear gradient</td>
</tr>
<tr>
<td>25–30</td>
<td>0</td>
<td>100</td>
<td>isocratic</td>
</tr>
<tr>
<td>30–32</td>
<td>0 to 100</td>
<td>100 to 0</td>
<td>linear gradient</td>
</tr>
<tr>
<td>32–40</td>
<td>100</td>
<td>0</td>
<td>re-equilibration</td>
</tr>
</tbody>
</table>

¹ An Ascentis Express C<sub>18</sub> column was found suitable.
Maintain the column temperature at 35 °C.

Prepare the following solutions using a mixture of 31 volumes of acetonitrile R and 69 volumes of water R as solvent. For solution (1) dissolve about 50 mg of the test substance in 10.0 mL and sonicate for about 10 minutes. Ensure that the temperature of the sonication bath is below room temperature to avoid degradation of misoprostol. For solution (2) dilute 1 volume of solution (1) to 500 volumes. For solution (3) heat 5 mL of solution (1) in a water bath at 75 °C for 1 hour.

Operate with a flow rate of 1.5 mL per minute. As a detector use an ultraviolet spectrophotometer set at a wavelength of 200 nm. Store the samples at 4 °C during analysis using a cooled autosampler.

Inject 20 μL of solution (3). The test is not valid unless the peak-to-valley ratio (Hp/Hv) is at least 5.0, where Hp is the height above the extrapolated baseline of the peak due to impurity A (with a relative retention of about 0.95 with reference to misoprostol (retention time about 21 minutes)) and Hv is the height above the extrapolated baseline at the lowest point of the curve separating the peak due to impurity A from the peak due to misoprostol.

Inject alternately 20 μL each of solutions (1) and (2).

The chromatogram obtained with solution (1) may show the following impurities at the following relative retentions with reference to misoprostol (retention time about 21 minutes):

- impurity E (1st peak): about 0.84;
- impurity E (2nd peak): about 0.86;
- impurity B (1st peak): about 0.90;
- impurity B (2nd peak): about 0.92;
- impurity A: about 0.95;
- impurity D: about 1.27;
- impurity C: about 1.37. Use also the chromatogram obtained with solution (3) to identify impurity A and C.

In the chromatogram obtained with solution (1):

- the sum of the areas of any peak corresponding to impurity A, B and E is not greater than 7.5 times the area of the principal peak in the chromatogram obtained with solution (2) (1.5 %);
• the area of any peak corresponding to impurity C, when multiplied by a correction factor of 0.76, is not greater than 0.75 times the area of the principal peak in the chromatogram obtained with solution (2) (0.15 %);

• the area of any other impurity peak is not greater than 0.5 times the area of the principal peak in the chromatogram obtained with solution (2) (0.1 %);

• the sum of the corrected area of any peak corresponding to impurity C and the areas of all other peaks, other than the principal peak, is not greater than 10 times the area of the principal peak in the chromatogram obtained with solution (2) (2.0 %). Disregard any peak with an area less than 0.25 times the area of the principal peak in the chromatogram obtained with solution (2) (0.05 %).

**Diastereoisomers**

Carry out the test as described under 1.14.4 *High performance liquid chromatography* using a stainless steel column (15 cm × 2.1 mm) packed with silica gel for chromatography R (3.5 μm).² As the mobile phase use a mixture of 4 volumes of 2-propanol R, 96 volumes of heptane R and 0.1 volume of trifluoroacetic acid R.

As the test solution use 1.0 mg of the test substance per mL of a mixture of 4 volumes of 2-propanol R and 96 volumes of heptane R.

Maintain the column temperature at 25 °C.

Operate with a flow rate of 0.5 mL per minute. As a detector use an ultraviolet spectrophotometer set at a wavelength of 205 nm. Store the samples at 4 °C during analysis using a cooled autosampler.

Inject 10 μL of the test solution.

The chromatogram shows two principal peaks due to misoprostol at retention times of about 14 and 16 minutes. The test is not valid unless the resolution between these two peaks is at least 2.0.

² A Xbridge HILIC column was found suitable.
Measure the areas of the two peaks corresponding to misoprostol. The first peak of misoprostol is 45%–55% of the sum of the areas of the two peaks due to misoprostol.

**Assay**

Carry out the test as described under *1.14.4 High performance liquid chromatography* using a stainless steel column (15 cm × 4.6 mm) packed with octadecylsilyl silica gel (5 μm). As the mobile phase use a mixture of 45 volumes of acetonitrile R and 55 volumes of water.

Prepare the following solutions in the mobile phase. For solution (1) use 0.1 mg of misoprostol per mL. For solution (2) use 0.1 mg of misoprostol RS per mL.

Maintain the column temperature at 35 °C.

Operate with a flow rate of 1.5 mL per minute. As a detector use an ultraviolet spectrophotometer set at a wavelength of 200 nm. Store the samples at 4 °C during analysis using a cooled autosampler.

Inject alternately 20 μL each of solutions (1) and (2). The test is not valid unless the symmetry factor of the peak due to misoprostol is between 0.8 and 1.5.

Measure the areas of the peak responses obtained in the chromatograms from solutions (1) and (2) and calculate the percentage content of misoprostol (C\textsubscript{22}H\textsubscript{38}O\textsubscript{5}), using the declared content of C\textsubscript{22}H\textsubscript{38}O\textsubscript{5} in misoprostol RS.

**Impurities**

\[
\begin{align*}
\text{its epimer at C}^* \quad \text{and their enantiomers}
\end{align*}
\]

A. Mixture of methyl \(rac\text{-}7\{-[(1R,2S,3S)\text{-}3\text{-}hydroxy-2\{-[(1E,4R)\text{-}4\text{-}hydroxy-4\text{-}methyloct-1-en-1\text{-}yl\text{-}5\text{-}oxocyclopentyl}\text{heptanoate and methyl }rac\text{-}7\{-[(1R,2S,3S)\text{-}3\text{-}hydroxy-2-}
\]

\footnote{An Ascentis Express C18 column was found suitable.}
[(1E,4S)-4-hydroxy-4-methyloct-1-en-1-yl]-5-oxocyclopentyl]heptanoate (8-
epimisoprostol)

B. Mixture of methyl 7-[(1RS,2SR,3RS)-3-hydroxy-2-[(1E,4RS)-4-hydroxy-4-methyloct-1-
enyl]-5-oxocyclopentyl]heptanoate and methyl 7-[(1RS,2SR,3RS)-3-hydroxy-2-
[(1E,4SR)-4-hydroxy-4-methyloct-1-enyl]-5-oxocyclopentyl]heptanoate (12-
epimisoprostol) (synthesis impurity)

C. Mixture of methyl rac-7-[(1R,2S)-2-[(1E,4R)-4-hydroxy-4-methyloct-1-en-1-yl]-5-
oxocyclopent-3-en-1-yl]heptanoate and methyl rac-7-[(1R,2S)-2-[(1E,4S)-4-hydroxy-4-
methyloct-1-en-1-yl]-5-oxocyclopentyl]heptanoate. (misoprostol A)

D. Methyl rac-7-2-[(1E,4R)-4-hydroxy-4-methyloct-1-en-1-yl]-5-oxocyclopent-1-en-1-
yl]heptanoate (misoprostol B)

E. (±) - methyl (1R,2R,3R)-3-hydroxy-2-[(1E,4RS)-(1,5-heptadien-1-yl)]-4-hydroxy-4,6-
dimethyl-5-oxocyclopentaneheptanoate [Note from the Secretariat. Chemical name to be confirmed.]

***